Theratechnologies (NASDAQ:THTX) Releases Earnings Results, Misses Expectations By $0.08 EPS

Theratechnologies (NASDAQ:THTX - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.08), Zacks reports. The business had revenue of $17,729 billion for the quarter, compared to analysts' expectations of $24.30 million.

Theratechnologies Stock Performance

Shares of NASDAQ THTX traded up $0.01 during trading on Thursday, reaching $3.15. The company had a trading volume of 409,125 shares, compared to its average volume of 890,821. Theratechnologies has a 52 week low of $1.12 and a 52 week high of $3.20. The stock has a market cap of $144.84 million, a PE ratio of -16.58 and a beta of 0.55. The business's 50 day moving average price is $2.63 and its 200-day moving average price is $2.10.

Hedge Funds Weigh In On Theratechnologies

A hedge fund recently raised its stake in Theratechnologies stock. Bank of America Corp DE increased its holdings in shares of Theratechnologies Inc. (NASDAQ:THTX - Free Report) by 1,416.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,487 shares of the company's stock after buying an additional 15,400 shares during the period. Bank of America Corp DE's holdings in Theratechnologies were worth $30,000 at the end of the most recent quarter.

Wall Street Analysts Forecast Growth

Separately, Jones Trading downgraded shares of Theratechnologies from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 3rd.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.